PDS0103 combines the utility of the Versamune^® platform with novel highly immunogenic agonist epitopes of mucin-1 (MUC1) oncogenic C-terminal region. MUC1 is highly expressed in multiple tumor types and has been shown to be associated with drug resistance and poor disease prognosis. PDS Biotech is developing PDS0103 for the treatment of ovarian, breast, colorectal and lung cancers.

PDS0103 is currently in late-stage pre-clinical development.